State of the Science Summit on A Summer of Progress: Updates from ASCO | Conference

Dr. Stilwill on Findings from the 2018 ASCO Annual Meeting in Melanoma

August 1st 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses exciting findings in melanoma from the 2018 ASCO Annual Meeting.

Dr. Ulahannan on Immunotherapy in Hepatocellular Carcinoma

July 31st 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses immunotherapy in hepatocellular carcinoma (HCC).

Dr. Yardley on the D-CARE Trial in Women With High-Risk Early Breast Cancer

July 31st 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the D-CARE trial in women with high-risk early breast cancer.

Melanoma Field Continues to Shift With Targeted Therapy, Immunotherapy Approvals

July 26th 2018

Joseph Stilwill, MD, addresses recent advances in melanoma and the focus of research moving forward.

Regulatory Decisions Propel Nonmetastatic CRPC Paradigm Forward

July 26th 2018

Mehmood Hashmi, MD, discusses the newly defined landscape of nonmetastatic castration-resistant prostate cancer, the potential with immunotherapy, and emerging imaging modalities.

Dr. Stilwill on Optimal Sequencing in Melanoma

July 24th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses optimal sequencing in melanoma.

Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

July 24th 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

Novel Combinations Advance Through RCC Pipeline

July 20th 2018

Peter J. Van Veldhuizen, MD, discusses available and emerging therapies for patients with kidney cancer.

Dr. Hashmi on Immunotherapy in Prostate Cancer

July 18th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

Dr. Kambhampati on the Impact of Next-Generation Sequencing in AML

July 18th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the impact of next-generation sequencing (NGS) in acute myeloid leukemia (AML).

Dr. Flinn on the RELEVANCE Trial in Follicular Lymphoma

July 17th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.

Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors

July 17th 2018

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Dr. Hashmi on Imaging Modalities in Prostate Cancer

July 13th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Dr. Talley on Clinical Trials for Patients With Chronic Leukemias

July 13th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Dr. Kambhampati on BCL-2 Inhibition in Acute Myeloid Leukemia

July 13th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses BCL-2 inhibition in acute myeloid leukemia (AML).

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

July 13th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.

Dr. Ganti on Lung Cancer Abstracts From the 2018 ASCO Annual Meeting

July 12th 2018

Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, discusses lung cancer abstracts that were presented at the 2018 ASCO Annual Meeting.

Dr. Ulahannan on the PRODIGE Trial in Pancreatic Cancer

July 11th 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Dr. Hashmi on Prostate Cancer Abstracts From the 2018 ASCO Annual Meeting

July 10th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the exciting abstracts in prostate cancer that were presented at the 2018 ASCO Annual Meeting.

NEXT PAGE
PREVIOUS PAGE